How I treat Diamond-Blackfan anemia

Blood

Volumn 116, Issue 19, 2010, Pages 3715-3723

  Vlachos, Adrianna ^a   Muir, Ellen ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ATOVAQUONE; BISPHOSPHONIC ACID DERIVATIVE; BUSULFAN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ERYTHROPOIETIN; IMMUNOGLOBULIN; INTERLEUKIN 3; IRON CHELATING AGENT; LANSOPRAZOLE; LENALIDOMIDE; LEUCINE; METOCLOPRAMIDE; PENTAMIDINE; PREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR; RANITIDINE; THYMOCYTE ANTIBODY;

AGRANULOCYTOSIS; ALTERNATIVE MEDICINE; BLACKFAN DIAMOND ANEMIA; CONTINUOUS INFUSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE REGISTRY; DRUG MEGADOSE; ERYTHROID CELL; EVALUATION; FRACTURE; GASTROINTESTINAL SYMPTOM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRON CHELATION; MOLECULE; PATIENT CARE; PATIENT MONITORING; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REMISSION; REVIEW; STEM CELL TRANSPLANTATION; TRANSFUSION;

EID: 78149435818     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-251090     Document Type: Review

References (74)

1. Dianzani I, Loreni F. Diamond-Blackfan anemia: a ribosomal puzzle. Haematologica. 2008;93(11):1601-1604.
2. Draptchinskaia N, Gustavsson P, Andersson B, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999;21(2):169-175. (Pubitemid 29070361)
3. Gazda HT, Zhong R, Long L, et al. RNA and protein evidence for haplo-insufficiency in Diamond-Blackfan anaemia patients with RPS19 mutations. Br J Haematol. 2004;127(1):105-113. (Pubitemid 39331113)
4. Gazda HT, Grabowska A, Merida-Long LB, et al. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2006;79(6):1110-1118. (Pubitemid 44868071)
5. Cmejla R, Cmejlova J, Handrkova H, Petrak J, Pospisilova D. Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia. Hum Mutat. 2007;28(12):1178-1182. (Pubitemid 350250381)
6. Farrar JE, Nater M, Caywood E, et al. Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood. 2008;112(5):1582-1592.
7. Gazda HT, Sheen MR, Vlachos A, et al. Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. Am J Hum Genet. 2008;83(6):769-780.
8. Doherty L, Sheen MR, Vlachos A, et al. Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2010;86(2):222-228.
9. Lipton JM, Ellis SR. Diamond Blackfan anemia 2008-2009: broadening the scope of ribosome biogenesis disorders. Curr Opin Pediatr. 2010;22(1):12-19.
10. Vlachos A, Ball S, Dahl N, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142(6):859-876.
11. Samuel GN, Strong KA, Kerridge I, Jordens CF, Ankeny RA, Shaw PJ. Establishing the role of pre-implantation genetic diagnosis with human leucocyte antigen typing: what place do "saviour siblings" have in paediatric transplantation? Arch Dis Child. 2009;94(4):317-320.
12. Kuliev A, Rechitsky S, Tur-Kaspa I, Verlinsky Y. Preimplantation genetics: Improving access to stem cell therapy. Ann N Y Acad Sci. 2005;1054:223-227. (Pubitemid 43031028)
13. Diamond LK, Wang WC, Alter BP. Congenital hypoplastic anemia. Adv Pediatr. 1976;22:349-378.
14. Vlachos A, Klein GW, Lipton JM. The Diamond Blackfan Anemia Registry: tool for investigating the epidemiology and biology of Diamond-Blackfan anemia. J Pediatr Hematol Oncol. 2001;23(6):377-382. (Pubitemid 32845667)
15. Orfali KA, Ohene-Abuakwa Y, Ball SE. Diamond Blackfan anaemia in the UK: clinical and genetic heterogeneity. Br J Haematol. 2004;125(2):243-252. (Pubitemid 38534978)
16. Glader BE, Backer K. Elevated red cell adenosine deaminase activity: a marker of disordered erythropoiesis in Diamond-Blackfan anaemia and other haematologic diseases. Br J Haematol. 1988;68(2):165-168. (Pubitemid 18078461)
17. Willig TN, Perignon JL, Gustavsson P, et al. High adenosine deaminase level among healthy probands of Diamond Blackfan anemia (DBA) co-segregates with the DBA gene region on chromosome 19q13: the DBAWorking Group of Societe d'Immunologie Pediatrique (SHIP). Blood. 1998;92(11):4422-4427.
18. Giri N, Kang E, Tisdale JF, et al. Clinical and laboratory evidence for a trilineage haematopoietic defect in patients with refractory Diamond-Blackfan anaemia. Br J Haematol. 2000;108(1):167-175. (Pubitemid 30089949)
19. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451(7176):335-339.
20. Quarello P, Garelli E, Carando A, et al. Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations. Haematologica. 2010;95(2):206-213.
21. Gazda HT, Sheen MR, Doherty L, et al. Ribosomal protein genes S10 and S26 are commonly mutated in Diamond-Blackfan anemia [abstract]. ASH Annual Meeting Abstracts. 2009;114:175.
22. Cmejla R, Blafkova J, Stopka T, et al. Ribosomal protein S19 gene mutations in patients with Diamond-Blackfan anemia and identification of ribosomal protein S19 pseudogenes. Blood Cells Mol Dis. 2000;26(2):124-132. (Pubitemid 30604892)
23. Verlinsky Y, Rechitsky S, Sharapova T, Morris R, Taranissi M, Kuliev A. Preimplantation HLA testing. JAMA. 2004;291(17):2079-2085.
24. Lipton JM, Atsidaftos E, Zyskind I, Vlachos A. Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer. 2006;46(5):558-564.
25. Stark AR, Carlo WA, Tyson JE, et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants: National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 2001;344(2):95-101.
26. Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics. 1998;101(5):E7.
27. Bachrach LK, Ward LM. Clinical review 1: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab. 2009;94(2):400-409.
28. Shapiro JR, Sponsellor PD. Osteogenesis imperfecta: questions and answers. Curr Opin Pediatr. 2009;21(6):709-716.
29. American Academy of Pediatrics. Immunocompromised children. In: Pickering LK, ed. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009:72-86.
30. American Academy of Pediatrics. Pneumocystis jirovecii infections. In: Pickering LK, ed. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009:536-540.
31. Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients: the importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*. Hemoglobin. 2006;30(2):219-227. (Pubitemid 43977324)
32. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-573.
33. Berdoukas V, Dakin C, Freema A, Fraser I, Aessopos A, Bohane T. Lack of correlation between iron overload cardiac dysfunction and needle liver biopsy iron concentration. Haematologica. 2005;90(5):685-686. (Pubitemid 40780888)
34. Wood JC. Cardiac iron across different transfusion-dependent diseases. Blood Rev. 2008;22(suppl 2):S14-S21.
35. Roggero S, Quarello P, Vinciguerra T, Longo F, Piga A, Ramenghi U. Severe iron overload in Blackfan-Diamond anemia: a case-control study. Am J Hematol. 2009;84(11):729-732.
36. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460-1465. (Pubitemid 41129616)
37. Pennell DJ. T2* magnetic resonance: iron and gold. JACC Cardiovasc Imaging. 2008;1(5):579-581.
38. Raman SV, Winner MW 3rd, Tran T, et al. In vivo atherosclerotic plaque characterization using magnetic susceptibility distinguishes symptom-producing plaques. JACC Cardiovasc Imaging. 2008;1(1):49-57. (Pubitemid 351445385)
39. Tanner MA, Porter JB, Westwood MA, et al. Myocardial T2* in patients with cardiac failure secondary to iron overload [abstract]. ASH Annual Meeting Abstracts. 2005;106:3838.
40. Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood. 2009;114(19):4021- 4026.
41. Vichinsky E. Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia. Pediatrics. 2008;121(6):1253-1256.
42. Cappellini MD, Taher A. Deferasirox (Exjade) for the treatment of iron overload. Acta Haematol. 2009;122(2):165-173.
43. Kontoghiorghes GJ. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin. 2009;33(5):332-338.
44. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360(9332):516-520.
45. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733-3737.
46. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-3744.
47. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102(5):1583-1587.
48. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102(1):17-24.
49. Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev. 2007;3:CD004839.
50. Henter JI, Karlen J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood. 2007;109(12):5157-5159.
51. Ozsoylu S. Oral megadose methylprednisolone for Diamond-Blackfan anemia. Blood. 1994;84(9):3245-3247.
52. Buchanan GR. Oral megadose methylprednisolone therapy for refractory Diamond-Blackfan anemia: International Diamond-Blackfan Anemia Study Group. J Pediatr Hematol Oncol. 2001;23(6):353-356.
53. Sumimoto S, Kawai M, Kasajima Y, Hamamoto T. Intravenous gamma-globulin therapy in Diamond-Blackfan anemia. Acta Paediatr Jpn. 1992;34(2):179-180.
54. Bejaoui M, Fitouri Z, Sfar MT, Lakhoua R. Failure of immunosuppressive therapy and high-dose intravenous immunoglobulins in four transfusion-dependent, steroid-unresponsive Blackfan-Diamond anemia patients. Haematologica. 1993;78(1):38-39.
55. Fiorillo A, Poggi V, Migliorati R, Parasole R, Selleri C, Rotoli B. Unresponsiveness to erythropoietin therapy in a case of Blackfan Diamond anemia. Am J Hematol. 1991;37:65.
56. Halperin DS, Estrov Z, Freedman MH. Diamond-Blackfan anemia: promotion of marrow erythropoiesis in vitro by recombinant interleukin-3. Blood. 1989;73(5):1168-1174.
57. Dunbar CE, Smith DA, Kimball J, Garrison L, Nienhuis AW, Young NS. Treatment of Diamond-Blackfan anaemia with haematopoietic growth factors, granulocyte-macrophage colony stimulating factor and interleukin 3: sustained remissions following IL-3. Br J Haematol. 1991;79(2):316-321.
58. Gillio AP, Faulkner LB, Alter BP, et al. Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3. Blood. 1993;82(3):744-751.
59. Olivieri NF, Feig SA, Valentino L, Berriman AM, Shore R, Freedman MH. Failure of recombinant human interleukin-3 therapy to induce erythropoiesis in patients with refractory Diamond-Blackfan anemia. Blood. 1994;83(9):2444-2450.
60. Gomez-Almaguer D, Gonzalez-Llano O. Danazol in the treatment of Diamond Blackfan anemia [abstract]. Blood. 1992;80:382a.
61. Leonard EM, Raefsky E, Griffith P, Kimball J, Nienhuis AW, Young NS. Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia. Br J Haematol. 1989;72(2):278-284. (Pubitemid 19151153)
62. Alessandri AJ, Rogers PC, Wadsworth LD, Davis JH. Diamond-Blackfan anemia and cyclosporine therapy revisited. J Pediatr Hematol Oncol. 2000;22(2):176-179.
63. Bobey NA, Carcao M, Dror Y, Freedman MH, Dahl N, Woodman RC. Sustained cyclosporine-induced erythropoietic response in identical male twins with Diamond-Blackfan anemia. J Pediatr Hematol Oncol. 2003;25(11):914-918. (Pubitemid 37413845)
64. Abkowitz JL, Powell JS, Nakamura JM, Kadin ME, Adamson JW. Pure red cell aplasia: response to therapy with anti-thymocyte globulin. Am J Hematol. 1986;23(4):363-371. (Pubitemid 17191524)
65. Abkowitz JL, Schaison G, Boulad F, et al. Response of Diamond-Blackfan anemia to metoclopramide: evidence for a role for prolactin in erythropoiesis. Blood. 2002;100(8):2687-2691.
66. Akiyama M, Yanagisawa T, Yuza Y, et al. Successful treatment of Diamond-Blackfan anemia with metoclopramide. Am J Hematol. 2005;78(4):295-298. (Pubitemid 40471122)
67. Leblanc TM, Da Costa L, Marie I, Demolis P, Tchernia G. Metoclopramide treatment in DBA patients: no complete response in a French prospective study. Blood. 2007;109(5):2266-2267. (Pubitemid 46348236)
68. Pospisilova D, Cmejlova J, Hak J, Adam T, Cmejla R. Successful treatment of a Diamond-Blackfan anemia patient with amino acid leucine. Haematologica. 2007;92(5):e66-e67.
69. Lee H, Lyssikatos C, Atsidaftos E, et al. Remission in patients with Diamond Blackfan anemia (DBA) appears to be unrestricted by phenotype or genotype [abstract]. ASH Annual Meeting Abstracts. 2008;112:3092.
70. Faivre L, Meerpohl J, Da Costa L, et al. High-risk pregnancies in Diamond-Blackfan anemia: a survey of 64 pregnancies from the French and German registries. Haematologica. 2006;91(4):530-533.
71. August CS, King E, Githens JH, et al. Establishment of erythropoiesis following bone marrow transplantation in a patient with congenital hypoplastic anemia (Diamond-Blackfan syndrome). Blood. 1976;48(4):491-498.
72. Vlachos A, Federman N, Reyes-Haley C, Abramson J, Lipton JM. Hematopoietic stem cell transplantation for Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Bone Marrow Transplant. 2001;27(4):381-386. (Pubitemid 32201346)
73. Orfali RF, Wynn RF, Stevens RF, Chopra R, Ball SE. Failure of red cell production following allogenic BMT for Diamond Blackfan anaemia (DBA) illustrates functional significance of high erythrocyte adenosine deaminase (eADA) activity in the donor [abstract]. Blood. 1999;94:Abstract 414.
74. Aghalar J, Atsidaftos E, Lipton JM, Vlachos A. Improved outcomes in Diamond Blackfan anemia treated via stem cell transplantation since the year 2000 [abstract]. ASH Annual Meeting Abstracts. 2009;114:3202.